JP2014525476A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014525476A5 JP2014525476A5 JP2014529840A JP2014529840A JP2014525476A5 JP 2014525476 A5 JP2014525476 A5 JP 2014525476A5 JP 2014529840 A JP2014529840 A JP 2014529840A JP 2014529840 A JP2014529840 A JP 2014529840A JP 2014525476 A5 JP2014525476 A5 JP 2014525476A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- serpinf2
- composition according
- binding molecule
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 32
- 239000003112 inhibitor Substances 0.000 claims 12
- 230000002401 inhibitory effect Effects 0.000 claims 12
- 102000003801 alpha-2-Antiplasmin Human genes 0.000 claims 9
- 108090000183 alpha-2-Antiplasmin Proteins 0.000 claims 9
- 102000003978 Tissue plasminogen activator Human genes 0.000 claims 8
- 108090000373 Tissue plasminogen activator Proteins 0.000 claims 8
- 102000004965 antibodies Human genes 0.000 claims 8
- 108090001123 antibodies Proteins 0.000 claims 8
- 229960000187 tissue plasminogen activator Drugs 0.000 claims 8
- 206010018987 Haemorrhage Diseases 0.000 claims 5
- 206010061255 Ischaemia Diseases 0.000 claims 5
- 206010030113 Oedema Diseases 0.000 claims 5
- 231100000419 toxicity Toxicity 0.000 claims 5
- 230000001988 toxicity Effects 0.000 claims 5
- 206010059512 Apoptosis Diseases 0.000 claims 4
- 229920002395 Aptamer Polymers 0.000 claims 4
- 210000002216 Heart Anatomy 0.000 claims 4
- 210000004185 Liver Anatomy 0.000 claims 4
- 210000000496 Pancreas Anatomy 0.000 claims 4
- 230000006907 apoptotic process Effects 0.000 claims 4
- 230000034994 death Effects 0.000 claims 4
- 229920003013 deoxyribonucleic acid Polymers 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 150000003384 small molecules Chemical class 0.000 claims 4
- 206010022114 Injury Diseases 0.000 claims 3
- 210000003734 Kidney Anatomy 0.000 claims 3
- 210000004072 Lung Anatomy 0.000 claims 2
- 206010060860 Neurological symptom Diseases 0.000 claims 2
- 230000000740 bleeding Effects 0.000 claims 2
- 231100000319 bleeding Toxicity 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 210000000056 organs Anatomy 0.000 claims 2
- 230000000241 respiratory Effects 0.000 claims 2
- 206010052639 Nerve injury Diseases 0.000 claims 1
- 102000001938 Plasminogen Activators Human genes 0.000 claims 1
- 108010001014 Plasminogen Activators Proteins 0.000 claims 1
- 102000012479 Serine Proteases Human genes 0.000 claims 1
- 108010022999 Serine Proteases Proteins 0.000 claims 1
- 210000003292 kidney cell Anatomy 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000002035 prolonged Effects 0.000 claims 1
- 210000001519 tissues Anatomy 0.000 claims 1
Claims (28)
- 必要とされる患者において、出血または浮腫による障害または死亡を防止するための医薬組成物であって、ＳｅｒｐｉｎＦ２活性または濃度を低減させる有効量のＳｅｒｐｉｎＦ２結合分子を含み、前記ＳｅｒｐｉｎＦ２結合分子の投与が、前記患者における出血または浮腫による障害または死亡を防止する、医薬組成物。
- 前記出血または浮腫は、神経、心臓、肝臓、膵臓、呼吸器、または腎臓の出血または浮腫である、請求項１に記載の医薬組成物。
- 前記結合分子は、抗体、ペプチド、ＤＮＡアプタマー、または小分子から選択される、ＳｅｒｐｉｎＦ２阻害剤である、請求項１に記載の医薬組成物。
- 前記ＳｅｒｐｉｎＦ２阻害剤は、抗体である、請求項３に記載の医薬組成物。
- 前記ＳｅｒｐｉｎＦ２阻害剤は、２８〜９１ナノモル／ｋｇの用量範囲で投与される、請求項４に記載の医薬組成物。
- 必要とされる患者において、組織プラスミノーゲン活性化因子（ＴＰＡ）毒性による障害または死亡を防止するための医薬組成物であって、ＳｅｒｐｉｎＦ２活性または濃度を低減させる有効量のＳｅｒｐｉｎＦ２結合分子を含み、前記ＳｅｒｐｉｎＦ２結合分子の投与が、ＴＰＡ毒性による障害または死亡を防止する、医薬組成物。
- 前記ＴＰＡ毒性は、出血、器官浮腫、またはアポトーシスを引き起こす、請求項６に記載の医薬組成物。
- 前記投与が、前記患者がＴＰＡに誘発される損傷の危険性にあることを判定する先行ステップを含む、請求項６に記載の医薬組成物。
- 前記ＴＰＡ毒性は、虚血または外傷に起因する、請求項６に記載の医薬組成物。
- 前記ＴＰＡ毒性は、神経、心臓、肝臓、膵臓、呼吸器、または腎臓の損傷を引き起こす、請求項６に記載の医薬組成物。
- 前記ＴＰＡは、４８時間以内に事前に前記患者に投与されている、請求項６に記載の医薬組成物。
- プラスミノーゲン活性化因子またはセリンプロテアーゼ酵素は、４８時間以内に事前に前記患者に投与されている、請求項６に記載の医薬組成物。
- 前記結合分子は、抗体、ペプチド、ＤＮＡアプタマー、または小分子から選択される、ＳｅｒｐｉｎＦ２阻害剤である、請求項６に記載の医薬組成物。
- 前記ＳｅｒｐｉｎＦ２阻害剤は、抗体である、請求項１３に記載の医薬組成物。
- 前記ＳｅｒｐｉｎＦ２阻害剤は、２８〜９１ナノモル／ｋｇの用量範囲で投与される、請求項１４に記載の医薬組成物。
- アポトーシスの予防を、それを必要とする患者において行うための医薬組成物であって、ＳｅｒｐｉｎＦ２活性または濃度を低下させる有効量のＳｅｒｐｉｎＦ２結合分子を含み、前記ＳｅｒｐｉｎＦ２結合分子の投与が、前記患者におけるアポトーシスを予防する、医薬組成物。
- 前記アポトーシスは、神経、心臓、肝臓、膵臓、肺、または腎臓の細胞に生じる、請求項１６に記載の医薬組成物。
- 前記結合分子は、抗体、ペプチド、ＤＮＡアプタマー、または小分子から選択される、ＳｅｒｐｉｎＦ２阻害剤である、請求項１６に記載の医薬組成物。
- 前記ＳｅｒｐｉｎＦ２阻害剤は、抗体である、請求項１８に記載の医薬組成物。
- 前記ＳｅｒｐｉｎＦ２阻害剤は、２８〜９１ナノモル／ｋｇの用量範囲で投与される、請求項１９に記載の医薬組成物。
- 必要とされる患者において、長期虚血を防止するための医薬組成物であって、前記患者においてＳｅｒｐｉｎＦ２濃度または活性を低減させる有効量のＳｅｒｐｉｎＦ２結合分子を含み、前記ＳｅｒｐｉｎＦ２結合分子の投与が前記長期虚血を防止する、医薬組成物。
- 前記長期虚血は、少なくとも４０分間現れている、請求項２１に記載の医薬組成物。
- 前記長期虚血は、神経、心臓、肝臓、膵臓、肺、または腎臓の組織に生じる、請求項２１に記載の医薬組成物。
- 前記投与が、前記患者が神経損傷を示す神経症状を有することを判定する先行ステップを含む、請求項２１に記載の医薬組成物。
- 前記神経症状は、Ｒａｎｋｉｎ １またはＮＩＨ Ｓｔｒｏｋｅ Ｓｃａｌｅ ４よりも重度かまたはそれと同等として分類される、請求項２４に記載の医薬組成物。
- 前記結合分子は、抗体、ペプチド、ＤＮＡアプタマー、または小分子から選択される、ＳｅｒｐｉｎＦ２阻害剤である、請求項２１に記載の医薬組成物。
- 前記ＳｅｒｐｉｎＦ２阻害剤は、抗体である、請求項２６に記載の医薬組成物。
- 前記ＳｅｒｐｉｎＦ２阻害剤は、２８〜９１ナノモル／ｋｇの用量範囲で投与される、請求項２７に記載の医薬組成物。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161531278P | 2011-09-06 | 2011-09-06 | |
| US61/531,278 | 2011-09-06 | ||
| PCT/US2012/053900 WO2013036596A2 (en) | 2011-09-06 | 2012-09-06 | Serpinf2-binding molecules and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014525476A JP2014525476A (ja) | 2014-09-29 |
| JP2014525476A5 true JP2014525476A5 (ja) | 2015-08-13 |
| JP6184410B2 JP6184410B2 (ja) | 2017-08-23 |
Family
ID=47832762
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014529840A Active JP6184410B2 (ja) | 2011-09-06 | 2012-09-06 | Ｓｅｒｐｉｎｆ２結合分子および使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11236176B2 (ja) |
| EP (1) | EP2753359B1 (ja) |
| JP (1) | JP6184410B2 (ja) |
| AU (1) | AU2012304635B2 (ja) |
| CA (1) | CA2846667A1 (ja) |
| WO (1) | WO2013036596A2 (ja) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016106186A1 (en) * | 2014-12-22 | 2016-06-30 | Translational Sciences, Inc. | Prophylaxis of thrombosis |
| EP4007812A1 (en) * | 2019-08-01 | 2022-06-08 | Alnylam Pharmaceuticals, Inc. | Serpin family f member 2 (serpinf2) irna compositions and methods of use thereof |
| KR20230005333A (ko) | 2020-04-30 | 2023-01-09 | 라리마 테라퓨틱스, 인코포레이티드 | 미엘린 관련 질환 및 미토콘드리아 관련 질환을 치료하기 위한 방법 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| EP0247091B1 (en) | 1985-11-01 | 1993-09-29 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| DE3777359D1 (de) | 1986-12-19 | 1992-04-16 | Teijin Ltd | Aminosaeuresequenz des menschlichen alpha 2-plasmininhibitors und cdns sowie diese aminosaeuresequenz codierende genomische dns. |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| EP0941345A2 (en) * | 1996-09-20 | 1999-09-15 | The General Hospital Corporation | Chimeric, humanized and single chain antibodies to alpha-2-antiplasmin |
| US6534035B1 (en) | 1998-05-29 | 2003-03-18 | President And Fellows Of Harvard College | Methods of inhibiting clot formation |
| AU6200599A (en) * | 1998-09-29 | 2000-04-17 | Leuven Research & Development Vzw | Use of compounds that reduce alpha2-antiplasmin in vivo for the preparation of acomposition for the treatment of ischemic stroke |
| US6411506B1 (en) | 2000-07-20 | 2002-06-25 | Rlx Technologies, Inc. | High density web server chassis system and method |
| EP1572864A4 (en) * | 2001-03-08 | 2008-02-13 | Immunex Corp | HUMAN SERPIN POLYPEPTIDE |
| AU2003301843A1 (en) | 2002-05-17 | 2004-06-07 | Human Genome Sciences, Inc. | 157 human secreted proteins |
| US7309774B2 (en) | 2003-02-07 | 2007-12-18 | The Board Of Regents Of The University Of Oklahoma | Antiplasmin cleaving enzyme |
| WO2006005583A2 (en) | 2004-07-12 | 2006-01-19 | Geneprot Inc. | Secreted polypeptide species involved in multiple sclerosis |
| US20090118162A1 (en) * | 2005-06-07 | 2009-05-07 | Regents Of The University Of Colorado | Inhibitors of serine protease activity and their use in methods and compositions for treatment of graft rejection and promotion of graft survival |
| US9150903B2 (en) | 2007-04-25 | 2015-10-06 | Translational Sciences Inc. | Method of increasing plasmin activity through antiplasmin conversion |
| WO2010071787A1 (en) * | 2008-12-17 | 2010-06-24 | Arizona Board Regents, A Body Corporate Acting For And On Behalf Of Arizona State University | Pancreatic cancer markers and uses thereof |
| EP2521918B1 (en) * | 2010-01-08 | 2015-03-25 | Cavadis B.V. | Determination of exosomal biomarkers for predicting cardiovascular events |
-
2012
- 2012-09-06 AU AU2012304635A patent/AU2012304635B2/en active Active
- 2012-09-06 JP JP2014529840A patent/JP6184410B2/ja active Active
- 2012-09-06 WO PCT/US2012/053900 patent/WO2013036596A2/en active Application Filing
- 2012-09-06 CA CA2846667A patent/CA2846667A1/en active Pending
- 2012-09-06 EP EP12830126.4A patent/EP2753359B1/en active Active
-
2014
- 2014-03-06 US US14/198,804 patent/US11236176B2/en active Active
-
2022
- 2022-02-01 US US17/590,744 patent/US20220298261A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Guo et al. | Coronavirus disease 2019 (COVID‐19) and cardiovascular disease: a viewpoint on the potential influence of angiotensin‐converting enzyme inhibitors/angiotensin receptor blockers on onset and severity of severe acute respiratory syndrome coronavirus 2 infection | |
| Thibault et al. | Long-term benefit of postconditioning | |
| Horstmann et al. | Profiles of matrix metalloproteinases, their inhibitors, and laminin in stroke patients: influence of different therapies | |
| Wang et al. | The role of HMGB1, a nuclear damage-associated molecular pattern molecule, in the pathogenesis of lung diseases | |
| Huang et al. | Histones activate the NLRP3 inflammasome in Kupffer cells during sterile inflammatory liver injury | |
| Speer et al. | Abnormal high-density lipoprotein induces endothelial dysfunction via activation of Toll-like receptor-2 | |
| Song et al. | Mesenchymal stem cell immunomodulation: In pursuit of controlling COVID-19 related cytokine storm | |
| O'Sullivan et al. | Nitric oxide-matrix metaloproteinase-9 interactions: biological and pharmacological significance: NO and MMP-9 interactions | |
| Wang et al. | Role of ACE2 in diastolic and systolic heart failure | |
| Wang et al. | Tissue inhibitor of metalloproteinase 1 (TIMP-1) deficiency exacerbates carbon tetrachloride-induced liver injury and fibrosis in mice: involvement of hepatocyte STAT3 in TIMP-1 production | |
| Zhao et al. | Role of glycogen synthase kinase 3β in protective effect of propofol against hepatic ischemia–reperfusion injury | |
| JP2014526517A5 (ja) | ||
| Toltl et al. | Activated protein C modulates inflammation, apoptosis and tissue factor procoagulant activity by regulating endoplasmic reticulum calcium depletion in blood monocytes | |
| Zhou et al. | ADAMTS13 protects mice against renal ischemia-reperfusion injury by reducing inflammation and improving endothelial function | |
| JP2014525476A5 (ja) | ||
| Chai et al. | Cardiac remodeling in heart failure: role of pyroptosis and its therapeutic implications | |
| BRPI0911469A8 (pt) | Inibidores de gm-csf e il-17 para terapia | |
| BR112014001587A2 (pt) | derivados de ácido 3-(tiazol-4-carbonil)- ou 3-(tiazol-2-carbonil) amino-propiônico substituídos e seu uso como produtos farmacêuticos | |
| JP2015512927A5 (ja) | ||
| Lana et al. | Nebulization of glutathione and N-Acetylcysteine as an adjuvant therapy for COVID-19 onset | |
| WO2013028070A3 (en) | Compounds for use in boosting coagulation | |
| WO2009099642A3 (en) | Proteomic analysis of active multiple sclerosis lesions | |
| Rengasamy et al. | Bioactive peptides and proteins as alternative antiplatelet drugs | |
| Mohsenikia et al. | Therapeutic effects of dendrosomal solanine on a metastatic breast tumor | |
| Abrahams et al. | Anthracycline-induced cardiotoxicity: targeting high-density lipoproteins to limit the damage? |